Professional Documents
Culture Documents
, 2011
, 2011
, 2013.
, 9
300
Roche d.o.o.,
.
.
.
.
. -
.
.
.
.
.
.
.
.
.
. -
a
. ,
.
.
,
,
, .
.
,
ERA EDTA.
.
( ),
, .
,
.
-
.
. ,
.
. , Roche.
.
,
.
, 2011........................................7
...............................................................................................................................9
1. ......... 11
2.
2011. ......................................................................................12
3.
...............................................................................................13
4.
2011. .....................................15
5.
2011. ..................................................... ................... 20
6.
31. 2011..................................................................................26
7. 2011. ...........................................................33
8. ,
1997. 2011. .................................................................................... 35
2011. ....................................................39
1.
( )..................................................................................43
2. Ke 2011.
( )......................44
3. 2011. .........48
....................................................................................................................53
Serbian Society f Nephrology
, 2011
ANNUAL REPORT ON DIALYSIS
AND KIDNEY TRANSPLANTATION IN
SERBIA, 2011
, 2013.
:
.
.
.
2011.
.
2011. .
,
ERA-EDTA.
- ,
.
, ,
( ) . ,
,
.
,
.
.
,
,
.
,
.
, 10. 2013.
, 2011
1.
.
1.
31.12. 2011.
Table 1. Number of dialysis and kidney transplantation centers in Serbia,
December 31st 2011
Treatment methods used
Number of centers
& y
Hemodialysis & Peritoneal dialysis
29
Hemodialysis
29
Kidney transplantation
2011. 57 . -
2009. ,
. ,
.
2011. :
Medicon
.
29 a, .
: , ,
,
.
11
, 2011
2.
2011.
2011. 100%.
,
,
.
. , ERA-EDTA
15
.
,
.
%
100
80
60
40
20
0
1997
1998
1999
2000
2001
2002
2003
2010
2011
: ( ),
( ), 2005-2008 ( )
*Method of data collection: aggregated data based on centre questionnaire (gray column), individual patient data (black
column), aggregated data collected retrospectively for the period 2005-2008 (white column)
1.
Figure 1. Response rate on the questionnaires sent to the centers for dialysis and kidney
transplantation
12
, 2011
1997.
2004.
.
1997.
2004.
,
2005.
,
2005.
.
.
3.
3.
5 311. 2 19
5 311. 2
(33%) 50 , 150 6
19 (33%) 50 ,
(11%) .
150 6 (11%) .
25
20
22
19
15
10
10
5
150-200
>200
0
<50
50-100
100-150
2.
2.
Figure
2. 2.
Distribution
of centers
according
to number
of patients
on maintenance
hemodilysis
Figure
Distribution
of centers
according
to number
of patients
on maintenance
and peritonal dialysis
hemodilysis and peritonal dialysis
2
2 .
. 2011.
2011.
2011.
2011.
13
, 2011
2.
2011. 2011.
Table 2. Number of patients on maintenance hemodialysis (HD) and peritoneal dialysis (PD) on
December 31st 2011, number of patients started hemodialysis and peritoneal dialysis in 2011
(HD)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
59
A
,
,
,
,
,
,
,
, Medicon
,
,
, FMC,
, FMC, .
, FMC,
,
,
, FMC
,
, FMC
Ho , Medicon
14
31.12.2011.
14
51
33
95
8
245
80
130
88
38
66
46
86
81
64
24
96
117
47
55
7
68
101
76
13
29
138
87
119
11
96
79
24
5
191
22
91
121
92
116
52
124
26
50
8
11
85
50
86
164
62
157
84
76
104
6
15
2011.
New in
2011
1
12
2
11
2
46
24
3
13
11
5
7
2
33
4
5
18
26
8
12
0
12
21
13
0
10
17
12
17
4
27
13
6
1
49
0
19
33
9
21
13
22
12
12
3
2
17
4
9
40
9
35
14
26
16
4
4
(PD)
31.12. 2011.
2011.
New in 2011
0
0
0
18
6
66
13
74
0
0
0
0
0
0
0
1
16
0
0
1
0
7
1
3
0
2
41
2
2
3
27
0
1
0
47
0
2
17
0
0
9
0
0
2
0
0
0
4
0
0
13
2
10
1
4
0
0
0
0
0
1
3
15
3
18
0
0
0
0
0
0
0
0
4
0
0
0
0
3
1
0
0
1
11
0
0
0
6
0
0
0
6
0
0
7
0
0
2
0
0
2
0
0
0
1
0
0
4
0
4
0
4
0
0
, 2011
2011. ,
Medicon
.
2011. 2010.
(78,1%
, 7,8% ).
ERA-EDTA.
(3,7%), (11,3%) [1].
10-20% , 20% ,
10-20% 20% .
29 ,
14 , .
, ,
8
58 , 1%
.
(CAPD),
(APD).
4.
2011.
2011.
ERA-EDTA .
, ,
.
15
, 2011
, (,
),
.
ERA-EDTA
.
ERA-EDTA 91. .
(,
pre-emptive kidney transplantation).
91.
.
.
3
2011. : 2011.
, 31. 2011. ,
2011.
2011. .
3.
2011.
Table 3. Main epidemiological data of patients on renal replacement therapy in
Serbia in 2011
1.
Number of new patients,
at day 1
31. 12. 2011.
Number of patients
Dec 31st 2011
2011. .
Number of patients
died 2011
O
( )
General population
(in thousands)
1043
5275
774
7259
4
2011.
16
, 2011
91. , 5
31. 2011.
.
4. 2011.
91.
Table 4. Data on patients who started renal replacement therapy in Serbia in 2011 and were on
the therapy at day 91
Hemodialysis
Peritoneal
dialysis
idny
transplantation
Total
(%)
91. .
Number (%) of new patients,
at day 91
847
(88,2)
100
(10,4)
13
(1,4)
960
(100)
91.
Number of patients
per milion population
at day 91
116,7
13,8
1,8
132,3
3 4
2011. 1043, 90
960 . 83 2011.
, 90 (8%)
. ERA-EDTA
91.
2% 17% ( , ) [1].
2011. 91. (960), 847 (88,2%)
, 100 (10,4%) ,
13 (1,4%) ( 4).
2011. 5275 : 4119 (78 %), 414 (8%), 738 (14 %) ( 5). 4
.
17
, 2011
5.
31. 2011.
Table 5. Data on renal replacement therapy patients in Serbia on December 31st 2011
(%)
31.12. 2011.
Number (%) of patients
Dec 31st 2011
31.12. 2011.
Number of patients
per milion population
Dec 31st 2011
Hemodialysis
Peritoneal
dialysis
idny
transplantation
4119
(78)
414
(8)
738
(14)
5275
(100)
568
57
102
727
Total
2011.
: 2010. 5546, 2011. 5275,
. ,
2011. .
. ,
2011. , , .
2011.
2010. ( 468 414),
2010. 2009. ( 504 468).
/
.
, , ,
.
2010. 31. 997
, 2011. 738.
18
, 2011
.
, .
.
2011. 772 , 90 2010.
.
741 688, 106 79,
2010.
10 5.
,
. , ,
.
3
1997. 2011. .
.
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
1997 1998 1999 2000 2001 2002 2003 2004
3.
3.
1997 2011.
1997
2011.
Figure
3. Distribution
of patients
according
to the
method
of renal replacement therapy in our
Figure 3.
Distribution
patients
to the method of renal replacement therapy
country
duringofthe
period according
1997 2011
19
ERA-EDTA 2010. 2011. ,
, 2011
ERA-EDTA 2010.
2011. ,
,
.
, 40%
, [1,2].
5.
2011.
2011. e 1043
.
(60,5 vs. 58,8 ).
, 2011. ,
6.
6.
2010.
Table 6. Data on patients started renal replacement therapy in 2010
All patients
Number
Incidence
Mean ge
,
New patients at
day 1
Incidence pmp at
day 1
, 91.
New patients at
day 91
143,7
91.
Incidence pmp at
day 91
132,3
20
1043
960
60,514,5
Males
Number
Incidence
Mean ge
637
60,514,3
180,4
59,514,5
592
167,7
Females
Number
Incidence
Mean ge
406
60,514,9
108,9
60,014,3
368
98,7
59,815,0
2011
,
(1043
,
188,6
).
(1043
1420
),
(143,7
(
3).
. 188,6
91.
).
91.
(
2011.
4). 2011.
,
,
,.
.
pmp
1420 ), (143,7 .
200
180
160
140
120
100
80
60
40
20
0
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
1.
91.
4. 4.
91.
91.
Figure
4. Incidence
rate of renal
replacement
therapy
patients per million population (pmp)
at day 1 and
91 of renal replacement therapy patients per million population
Figure 4. Incidence
rate
4 2005. 2010.
91.
4
62
2005. ,
2010.
43
91. 2435%.
2011.
91.
83
,
43 62
8,0%.
91. 2435%. 2011.
91. .
83 ,
8,0%.
-
,
91.
. ,
.
-
21
,
. ,
,
2011
pmp
.
,
91.
91.
ERA-EDTA [1,2].
ERA-EDTA [1,2].
500
450
400
350
300
250
200
150
100
50
0
0-19
20-44
45-64
65-74
75+
5.
5.
91.
91.
Figure 5. Distribution of patients on renal replacement therapy at day 91 according to age
Figureand
5. gender
Distribution of patients on renal replacement therapy at day 91 according to
age and gender
91.
91.
.
.
6574 , 75
6574 ,
( 426 146
75 ( 426
).
146 ).
22
, 2011
7.
2011.
91.
( )
Table 7. Causes of end-stage renal disease in all patients started renal replacement therapy in
2011 and those on treatment at day 91 presented as incidence rate (pmp) and percent
Diagnosis
1.
at day 1
91.
at day 91
I/pmp
I/mp
Glomerulonephritis
13,5
9,4
13,2
10,0
Pyelonephritis
16,3
11,3
13,9
10,5
Balkan nephropathy
3,2
2,2
Polycystic kidney disease
8,8
6,1
8,5
6,5
31,3
21,8
30,0
22,7
36,2
25,2
34,4
26,0
Renovascular disease
0,4
0,3
0,4
0,3
Miscellaneous
20,6
14,3
19,8
15,0
Unknown
13,4
9,3
11,8
9,0
Diabetes
Hypertension
2011. (Ta 7),
.
2011.
.
2011.
,
ERA-EDTA. ( )
39,4% [1]. ERA-EDTA , 23
, 2011
,
[1-3].
.
, ,
.
90
81
80
70
60
50
40
30
20
10
0.4
0
HDcentar
HD-kua
6.8
HDF
10
0.4
APD
CAPD
1.1
0.2
Tx-ivi
dav.
Tx-kad.
6. 6.
91.
91. (
91. )
91. )
Figure 6. Methods
of renal replacement therapy used in new patients at day 91 (presented as
percentages
number
of patients regisetred
day 91)
Figure 6. Methods ofoftotal
renal
replacement
therapy atused
in new patients at day 91
6
91. .
6
2009.
2011.
,
91.
.
4%.
2009. 2011. ,
,
4%.
1,3% ,
1,3% ,
2,1% (, )
24
15,9% ().
, 2011
100
90
80
70
60
50
40
30
20
10
0
0-19
20-44
45-64
65-74
75+
(kidney transplantation)
7.
91.
7.
Figure
7.
Distribution
of
patients
on
established
renal
replacement
therapy
methods at day 91
91.
according to age
Figure 7. Distribution of patients on established renal replacement therapy methods at
c
2011.
( 7).
2011.
(
7). X
. 9 ,
, .
.
,
9 , ,
2044 .
. ,
2544 .
25
, 2011
6.
31. 2011.
31. 2011.
.
8.
31. 2011.
Table 8. Data on patients on renal replacement therapy in Serbia on December 31. 2011
All patients
Males
Females
Number
(Prevalence, pmp)
Age, years
Number
(Prevalence,
pmp)
Age, years
Number
(Prevalence,
pmp)
Age, years
5275
(726,7)
57,014,3
3143
(887,6)
57,014,2
2141
(574,3)
57,114,5
2011. 727 ( 8).
ERA-EDTA
2011. 802 ()
1271 (, ) [1], 2010. 1752 [4]. A
ERA-EDTA 2011. 705
624 [1].
1997,
,
2010. . 1997. 435
305
2010. ( 9).
2011. , .
26
, 2010.
. 1997. 435
305 2010.
, 2011
( 9). 2011.
, .
8 2011.
8 2011.
(59,5%) (40,5%),
(59,5%) (40,5%),
2011. .
2011. .
ERA-EDTA [1]. ERA-EDTA [1].
2011. 57
2011. 57 , 5,5
, 5,5 1999. [5].
1999. [5]. ERA-EDTA
ERA-EDTA 2011.
2011. 55 ()
55 () 65,1 (,
65,1 (, ) [1].
) [1].
2500
pmp
2000
1500
1000
500
0
0-19
20-44
45-64
65-74
75+
8.
31.
8.
Figure 8. Distribution of patients on renal replacement therapy in Serbia on December 31st
31.
according to age and gender
Figure 8. Distribution of patients on renal replacement therapy in Serbia on December
31st according to age and gender
31. 2011.
.
8 .
6574 , 918
75 .
19 , ,
.
27
28
2009
2010
2011
100
100
100
73,9
71,7
71,7
71,7
83,0
60,2
90,4
96,2
92,3
92
93,9
92,6
RR
7,3
7,5
7,5
7,6
7,4
7,4
7,4
8,5
8,5
8,5
8,5
8,5
8,5
8,5
10,6
POP
1043
1420
1332
1349
1208
1093
1150
635
573
1112
977
985
958
1042
1149
Ni
144
189
179
178
175
158
167
95
117
137
115
116
113
123
108
Ni/P
774
862
871
636
635
662
563
783
736
689
677
680
953
No
106
115
116
97
92
96
82
96
87
81
80
80
90
No/P
5275
5546
5208
4493
3990
3689
3530
2700
2398
3997
4224
3961
3604
3785
4615
Ns
727
740
699
686
578
535
512
402
491
492
497
466
424
445
435
Ns/P
41,0
74,4
61,5
93,8
77,4
58,2
79,3
40,7
28,3
34,8
33
42,6
18,5
(Ni-No)/P
RR =
POP =
Ni =
Ni/P =
No =
No/P =
Ns = 31.
Ns/P =
(Ni-No)/P =
Ki =
Ko= No/Ns ()
K linear = Ki Ko
2007
2008
2005
2006
2004
2002
2003
2000
2001
1999
1998
1997
19,8
25,6
25,6
30,1
31,2
30,5
33,5
23,6
23,8
27,8
23,1
24,9
26,5
27,5
24,4
Ki
14,7
15,5
16,7
14,6
16,4
18,5
16,3
19,6
17,4
17,4
18.8
17,9
20,7
Ko
9
1997-2011.
Table 9. Epidemiological data on end-stage renal disease patients in our country from 1997-2011
5,1
10,1
8,9
15,5
14,8
12,0
17,2
8,2
5,7
7,5
7.7
9,6
4,2
K linear
, 2011
, 2011
10.
31. 2011. e
able 10. Frequency of end-stage renal disease causes in patients on renal replacement therapy
on December 31st 2011
Diagnosis
Prevalence, pmp
Glomerulonephritis
153,6
21,1
Pyelonephritis
85,0
11,7
Balkan nephropathy
34,5
4,7
Polycystic kidney disease
51,7
7,1
Diabetes
95,1
13,1
Hypertension
170,3
23,4
Renovascular disease
7,9
1,1
Miscellaneous
86,0
11,8
Unknown
42,7
5,9
10
31. 2011. e.
.
.
,
[4],
[1].
.
2009.
137,7
, 32,6 2011.
. .
29
, 2011
,
( 10, 9).
,
.
.
10 ,
ERA-EDTA
. , .
: 37,9 2009. , 31,6 2010. 34,5
2011. .
30
25
20
15
10
5
0
2000
2011
(Glomerulonephritis); (Pyelonephritis);
(Pyelonephritis);
(Glomerulonephritis);
(Balkan nephropathy);
(Polycystic
kidney disease); (Polycystic kidney disease);
(Balkan
nephropathy);
mellitus);
(Hypertension)
(Diabeltes
(Diabeltes
mellitus);
(Hypertension)
9.
9.
2000. 2011.
.
2000
2011
(
31.
( 31. )
)
Figure 9. Frequency of end-stage renal disease causes in patients on renal replacement therapy
in 2000 and 2011 (on December 31)
30
31.
2000 2011 .
, 2011
[6,7].
[6,7].
63.1
60
50
40
30
20
14.3
7.6
10
0.6
0
HD-centar
HD-kua
9.5
0.3
HDF
APD
CAPD
Tx-ivi
davalac
4.5
Tx-kadaver.
Davalac
10.
10.
31.
2011.
31. 2011.
Figure 10. Percent of established renal replacement therapy methods in prevalent patients on
Figure 10. Percent of established renal replacement therapy methods in prevalent
December 31st 2011.
patients on December 31st 2011.
2011.
o
2011.
(333063,1%),
(333063,1%),
754 (14,3%) (
10).
754 (14,3%)
10).
413 (7,9%)
(
413 (7,9%)
(3997,6%).
2011.(3997,6%).
14%
2011. 14%
, 31
.
, 2011
,
. 40%
,
(61.8%) (71,9%).
6,6% 34,4%,
[1,8].
100
80
60
40
20
0
0-19
20-44
45-64
65-74
75+
- (hemodialysis);
(hemodialysis); -
dialysis);
-
-
(peritoneal
(peritoneal
dialysis); -
-
(kidney transplantation)
(kidney transplantation)
11.
91.
11.
Figure 11. Distribution of patients on established renal replacement therapy methods at day 91
91.
according to age
Figure 11. Distribution of patients on established renal replacement therapy methods at
day 91
according to age
c
2011.
c
( 11).
2011.
X
( 11).
X
,
. , , . 9 ,
2044
, . ,
.
2544 .
32
, 2011
7.
2011.
2011. o 113 ,
44 (38,9%) , 69 (61,13%)
. 2011.
. 13,4 ( ) 2010. 15,6 2011.. ,
2011.
(69 44) ( 11).
11. Te 2011.
Table 11. Kidney transplantations performed in 2011
Total
Living
Related
Unrelated
Type unknown
Deceased
(%)
Number (%)
113
28 (24,8%)
3 (2,7%)
13 (11,5%)
69 (61,1%)
Number pmp
15,6
3,9
0,4
1,8
9,5
11 13
.
13 , 2011. , 20 ERA-EDTA
. ,
(21), (22)
.
ERA-EDTA,
20, . ,
,
.
33
, 2011
Donor
(%)
Number (%)
Prevalence, pmp
Total
Living
Deceased
Type unknown
501 (67,9%)
237 (32,1%)
0 (0%)
738 (100%)
71,7
31,6
103,3
800
600
400
200
0
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
12.
12
1997. 2011.
1997. 2011.
Figure
12. tal
number of patients with transplanted kidney in period 1997- 2011 and number
Figureof12.
tal number
of patients
with transplanted
kidney in period 1997- 2011 and
patients
transplanted
in presented
years
34
, 2011.
.
,
, 2011
2011. . , .
8.
,
8. ,
1997.
2011.
1997. 2011.
13
1997.
2011. 13
.
1997. 2011.
1997. 2005. 108 167
. 1997.
, 2010. .
2005. 108 167 ,
2010. .
[9-11].
,
[9-11]. ,
, , , ,
.
.
800
700
600
pmp
500
400
300
200
100
20
11
20
10
20
09
20
08
20
07
20
06
20
05
20
04
20
03
20
02
20
01
20
00
19
99
19
98
19
97
13.
K
13. K
1997.
2004.
Figure 13.Figure
Changes
in incidence
and prevalence
of renal
replacement
therapy
patients
in in
our
13. Changes
in incidence
and prevalence
of renal
replacement
therapy
patients
country from 1997 to 2011
our country from 1997 to 2011
35
, 2011
2011.
2011.
ERA
, EDTA ( 14). 2011.
ERAEDTA ( 14).
2011.
.
2010.
( 13)
2010.
(
13)
1000
( 14).
1000 ( 14).
125
130
, ERA
149
189
960
939
, ERA
727
737
,
0
200
400
600
2010
800
1000
1200
2011
14.
14.
(
)
)
ERAEDTA (ERA) () 2010.
,
15
31.
,
20,7%
1997.
2011. .
31.
1997.
2011.
1997.
17,4 19,6%
. ,
, 16,3%.
14,6 18,5%, .
36
. 20,7% 1997.
17,4 19,6% .
, , 16,3%.
14,6
18,5%,
2011
,
25
20.7
20
17.9
18.8
19.6
17.4 17.4
18.5
16.3
16.4
15.5
14.7
15
16.8
14.6
10
5
0
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
15.
(%)
(%)
15.
1997.
2011.
o
1997. o2011.
FigureFigure
15. Mortality
(%)(%)
of patients
on on
renal
replacement
15. Mortality
of patients
renal
replacementtherapy
therapyfrom
from 1997
1997 to
to 2011
2011
.
,
2011.
.
2011.
,
.
,
.
,
.
.
25
20
19.8
16.6
14.7
15
10
5
1.0
0
16. 2011.
16. 2011.
31.
2011
2011
31.
established therapy
37
16 ,
, 2011
16
, 31. 2011.
.
2010. ,
, 2011. .
14.5
10.1
3.6
9.1
6.2
17.4
37.8
10
15
20
25
30
35
40
- (cardiovascular diseases); -
- (cardiovascular diseases); -
(cerebrovascular diseases); - (gastrointestinal diseases)
(cerebrovascular diseases); - (gastrointestinal diseases)
17.
17.
2011.
2011.
of death of renal replacement therapy ptients in 2011
Figure
17. Causes
Figure
17. Causes of death of renal replacement therapy ptients in 2011
17
17
2011. .
2011.
.
6,7%
.
, 6,7%
.
.
2011.
414
113
,
2011.
414
34
34
113 ,
.
,
.
2011. ,
38
, 2011
.
. 2011.
2001. [12]
, 2001.
18.
[12] 18.
30
25
20
HBV 2001
HBV 2011
15
HCV 2001
HCV 2011
10
5
0
HD
PD
Tx
18.
18.
2011.
Table
18. Percentage
of hepatitis B and hepatitis C positive patients treated with renal
2011.
replacement therapy in Serbia in 2011
Figure 18. Percentage of hepatitis B and hepatitis C positive patients treated with renal
replacement
therapy in
Serbia in 2011
18
18
2001. 2011. .
.
,
2001. 2011. .
anti-HCV .
,
anti-HCV .
39
, 2011
1.
40
Serbian Society f Nephrology
, 2011
ANNUAL REPORT ON VASCULAR ACCESS
FOR HEMODIALYSIS IN
SERBIA, 2011
, 2013.
e
.
, 2011
1.
( )
57 , 2011. 53 . , ,
94,7% e
83,6%.
4171 3249 (92,7%) ,
(91,9%).
(3,2% 3,8%)
(4,1% 4,3%) . ( 1).
1.
31. 2011.
Table 1. Prevalence of certain types of vascular access in patients treated with hemodalysis in
Serbia on 31st December 2011
Vascular Access
Arteriovenous fistula
Vascular Graft
/Arm
(%)
Number (%)
3868 (92.7%)
87 (2,1%)
/Leg
45 (1,1%)
/Overall
132 (3,2%)
()
Vascular Catheters (VC)
-/ VC-J
67 (1,6%)
-/VC-SC
91 (2,2%)
-/VC-F
13 (0,3%)
/Overall
171 (4,1%)
Vascular Access, Overall
4171 (100%)
-= , -K =
-=
VC-J= vascular catheter, jugular, VC-SC= vascular catheter, subclavian,
VC-F=vascular catheter, femoral
43
, 2011
The Dialysis Outcomes and Practice Patterns Study - DOPPS III
, - 50% , 70% 47%
[1].
91% .
(,Fistula first)
32% 2003.
60,6% 2012. [2].
2.
KE
2011.
( )
, . ,
, o ( ) ,
.
1.
1.
Figure
1. Dialysis centers
that create
the greatest
number
vascular
access
with a number of
of
Figurereferral
1. Dialysis
centers centers that create the greatest number of vascular access with a
2011.
,
,
,
, , ,
44 .
( 2).
, 2011
.
( 2).
( , , ),
, .
, ,
,
.
2.
2011.
Table 2. Number of particular vascular access created in referent centers in 2011
Overall
AVF
AVG
arm
AVG
leg
-
VC-J
-
VC-SC
-
VC-F
Preemptive
AVF
267
165
35
29
21
259
250
172
145
113
109
106
104
76
71
64
64
62
61
59
55
44
42
44
40
40
39
32
23
32
31
31
23
29
29
20
19
18
18
Center
2
22
28
24
7
14
11
24
1
3
1
2
1
1
22
13
1
1
6
8
11
3
4
2
45
, 2011
17
16
16
15
13
15
15
13
13
12
12
10
10
1574
(100)
1378
(87,6)
,
(%)
Overall,
No(%)
13
1
8
67
(4,3)
16
(1,0)
65
(4,1)
26
(1,6)
22
(1,4)
203
(14,7)
-= , -K =
-=
VC-J= vascular catheter, jugular, CV-SC= vascular catheter, subclavian,
VC-F=vascular catheter, femoral
#
*
,
(87,6%)
(5,3%) (7,1%) ( 2).
, .
,
-Vascular
Access Society [3] .
, 83 (5,3%),
(4,3%), (3,3%). O
u 2011. 14,7% je , (7,3%).
, .
46
(arteriovenous
fistula),
=
(arteriovenous
fistula), =
(vascular
catheter,
jugular)r,
=
(vascular
catheter, subclavian),
(vascular
catheter,
jugular)r,
=
(vascular
catheter,
subclavian),
(vascular
catheter, catheter,
femoral) femoral)
(vascular
2.
2011.
2.
2011.
Figure
2. The number and type of vascular access created in Serbia in 2011
Figure 2. The number and type of vascular access created in Serbia in 2011
2
.
.
3, 313,
(59%) (59%)
31
,
. .
, 29
29
( ).
( ).
. 7 ,
. 7 , 14% 10
14%
10 .
.
,
,
,
.
,
.
47
,
.
, 2011
7 (14%)
29 (56%)
15 (30%)
<10
>10
3. 3.(%)
(%)
Figure
3. Number
(%) ofcenters
dialysis
that create
pre-emptive
arteriovenous
Figure
3. Number
(%) of dialysis
that centers
create pre-emptive
arteriovenous
fistula
3.
fistula
3.
2011.
2011.
2011.2011.
(1021),(1021),
(65%)
663
663
(65%) ( 4).
( 4).
358 (36% )
358 (36% )
663 (64% )
663 (64% )
= ca ,
with vascular catheter
= ,
without vascular catheter
4.
sa
=(%)
ca
,
with
vascular
catheter
2011.
2011.
,
4. (%)
()
2011. ,
48
Figure
() 4. Number (%) of incident patients who started hemodialysis with/without
vascular
in incident
2011 patients who started hemodialysis with/without
Figure 4.catheter
Number()
(%) of
, 2011
32
( 32 ).
8 , 4 .
,
.
5.
5.
(%)
(%)
5.
(%)
Figure 5.Figure
Number
of centers
that
set temporary
vascular catheters
hemodialysis
5. (%)
Number
(%) of
centers
that set temporary
vascularforcatheters
for hemodialysis
Figure 5. Number (%) of centers that set temporary vascular catheters for hemodialysis
5. (%)
re 5. Number (%) of centers that set temporary vascular catheters for hemodialysis
(vascular
catheter,
jugular),
=jugular),
(vascular
catheter,
(vascular
catheter,
subclavian),
=
(vascular catheter,
(vascular
catheter,
subclavian),
=
=
(vascular
catheter,
jugular),
=
femora)l
=
(vascular
catheter,
femora)l (vascular catheter,
(vascular
catheter,
subclavian),
=
femora)l
6.
6.
6.
49
, 2011
,
2011. 2011.
(97%
).
(97% ).
(66%
60%),
(66% 60%),
(59% 73%),
(59% 73%),
( 6).
( 6).
,
,
.
.
(vascular
catheter,
femoral)
=
(vascular
catheter,
jugular),
=
7.femora)l
(%)
7. (%)
of(%)
Figure 7.
Number
temporary
vascular
catheters
thatare
used as
permanent
vascular
hemodialysis
access for
Figure 7. Number (%) of temporary vascular catheters that are used as permanent
vascular access for hemodialysis
( 152 ).
(
152
).
(60%), (31%)
(9%), 7. ,
,
.
50
, 2011
1.
2.
3.
Ethier J, Mendelssohn DC, Elder SJ, Hasegawa T, Akizawa T, Akiba T, Canaud BJ,
Pisoni RL. Vascular access use and outcomes: an international perspective from
the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant.
2008; 23(10): 3219-3226.
http://www.fistulafirst.org, About Fistula First, Fistula First Catheter Last (FF/
CL) Data, July 2003 April 2012 Graphs, Graphs of Prevalent AV Fistula Use
Rates, By Network. Accessed on September 9, 2013.
http://www.vascularaccesssociety.com Vascular Access Society, Home Page,
Guidelines, 10. Central venous access, Guidelines 10.3. Accessed on September
10, 2013.
51
:
:
:
:
:
:34300
: 069 8166 766
: 034 713 262
E-mail: bolnica.ar@open.telekom.rs
:
:
: O
:
: I 26
:21400
: 021 750 380
: 021 751 105
E-mail: dijalizabp@gmail.com
:
:
:
: .
: 2
:11000
: 011 366 2421
: 011 361 7127
E-mail: radomirnaumovic450@gmail.com
:
:
:
: .
: 10
:11000
: 011 206 0765
: 011 3612 858
E-mail: dijaliza@udk.bg.ac.rs
:
: -
:
: .
: 161
:11000
: 011 381 0458
: 011 3806977
E-mail: dim@eunet.rs; nefrolog@ptt.rs
55
:
:
:
: . .
: 17
:11000
: 011 266 2502
: 011 266 2502
E-mail: nefron_drjovanovic@yahoo.com
:
: K-
: ,
: -
: 9
:11080
: 011 3772 722
: 011 3772 758
E-mail: sanmil@beotel.net
:
:
: .
: 27
:11550
: 011 8120 164
: 011 8123 173
E-mail: nefropatija@eunet.rs nefropatija@ absolutok.net
:
: ,
:
:
: 91
:11460
: 011 7872 111
: 011 8300 182
E-mail: dzbarajevo9@gmail.com
:
:
:
: .
: 2
:11400
: 011 8231 988
: 011 8230 161
E-mail: admin.sbib@open.telekom.rs
56
:
:
:
: 231
:11500
: 011 8721 560
: 011 8123 560
E-mail: hemodijaliza.obrenovac@gmail.com
:
: Medicon
: . -
: 17 :11070
: 011 313 10 32
: 011 313 10 27
E-mail: bolnicanbg@medicon.rs
:
: . Fresenius Medical Care
: .
: 11
:11000
: 011 2852 445
: 011 2852 435
E-mail: cedomir.cuckovic@fmc-ag.com
:
: . Fresenius Medical Care
: .
: 63
:11000
: 011 2444 333
: 011 245 9040
E-mail: nikola.lazic@fmc-ag.com
: -
: . Fresenius Medical Care
: ,
: 11
:11070
: 011 2280 522
: 011 2289 712
E-mail: veselin.skataric@ fmc-ag.com
57
:
:
:
:
: 1
:19210
T: 030 422 777 . 251
:030-435 228
E-mail: zcbor@sezampro.rs
:
:
: -
:
:
:14000
: 014 295 288
: 014 221 330
E-mail: nefrologija@zcvaljevo.com
:
:
:
: .
: . . 1
:17500
: 017 427 044
: 017 405 126
E-mail: zivulovic.desimir@gmail.com
:
:
:
:
:
:21460
: 021 7954 507
:
E-mail: dijalizaobv@gmail.com
:
:
:
:
: ..
:26300
: 013 832 271
: 013 833 124
E-mail: obvrsac@eunet.rs
58
:
:
:
:
:
:12320
: 012 643 140
: 012 643 144
E-mail: dzzagubica@gmail.com
:
:
: ,
: .
:
:19000
: 019 445 646
: 019 420 672
E-mail: hdzcza@gmail.com
:
:
: ,
: .
: 5
:23000
: 023 513 390
: 023 513 374
E-mail: dijaliza.zrenjanin@yahoo.com
:
: O
: -
:
: 110
:23300
: 0230 434 603
: 0230 422 513
E-mail: dijalizakikinda@yahoo.com
:
:
:
: 1-3
:19320
: 019 801 455
: 019 802 851
E-mail: zckld@kladovonet.com
59
:
:
:
:
: 10
:38220
: 028 423 994
: 028 425 546
E-mail: zcentarkm@ open.telekom.rs
:
:
: ,
:
: 30
:34000
: 034 370 302, 034 50 52 26 : 034 370 302
E-mail: uprava@kc-kg.rs
:
:
:
:
:36000
: 036 301 872
:
E-mail: hemod@zcstudenica.org
:
:
`: -
:
: 16
:37000
: 037 414 097
: 037 424 039
E-mail: bataandric@gmail.com
:
:
:
: 027 385160
: 2
: 027 -381 335
: 027 -381 595
E-mail: dijaliza.dzkursumlija@gmail.com
60
:
:
:
: . , mr sc
: K 9
:16000
: 016 -252 500
: 016 344 4 501
E-mail: miodrag.sokolovic@googlemail.com
:
: .
`: ,
: .
: 65
:15300
: 015 873 333
: 015 873 344
E-mail: zcmarin@sezampro.rs
:
:
:
: -
: 4
:19300
: 019 542 951
: 019 544 296
E-mial: zcnuprava@nadlanu.com
:
:
:
: .
: 48
:18000
: 018 4530 856
: 018 530 127
E-mail: nefrologija@yahoo.com
:
:
:
:
: :18000
: 018 508 919
:
E-mial: vb.nis@mod.gov.rs
61
:
: . Fresenius Medical Care
:
: 94
:18000
: 018 207 713
: 018 207-710
E-mail: Vekoslav.Mitrovic@fmc-ag.com
:
:
: , dr sc
: 1
:36300
: 020 321 296
: 020-311-764
E-mail: ehadzi_dr@verat.net
:
:
:
: .
: 1-3
:21000
: 021 484 3984
:
E-mail: nefroim@eunet.rs
:
: . Medicon
:
: 11, . 42 :21000
: 021 545 060
: 021 545 060
E-mail: bolnicans@medicon.rs
:
: . Fresenius Medical Care
: , dr sc
: 2
:21000
: 021 4791 400
: 021 6312 323
E-mail: vasilije.tomanoski@fmc-ag.com
62
:
:
:
:
: 11
: 26000
: 013 319 900
: 0013 317 956
E-mail: gosavojinovic@yahoo.com
:
:
: -
:
:18300
: 010 305 283
: 010 305 349
E-mail: nefrologija.dijaliza@open.telekom.rs
:
:
:
: . .
: 135
:12000
: 012 550 222
: 012 550 585
E-mail: mdmart@ptt.rs
:
: ,
: O
:
: 1
:31300
: 033 712 975
: 033 714 166
E-mail: biljanagojakovic@hotmail.com
:
:
:
:
: 2
:18400
: 027 324 000 . 106
: 027 324 762
E-mail: zorica.radosevic.zoka@gmail.com
63
:
:
: ,
:
: 64
:24400
: 024 815 111
:
E-mail: hemodijalizasenta@gmail.com
:
: ,
:
:
: 10
:36310
: 020 741 226
: 020 741 226
E-mail: domzdravljasj@open.telekom.rs
:
:
: ,
:
: 51
:11300
: 026 223 522 / 161
: 026 221 346
E-mail: ob.smederevo@yahoo.com
:
:
: .
: 147
:11420
: 026/330-319
: 026 313 075
E-mail: svisoki7@open.telekom.rs
:
:
:
:
: 75
:25000
: 025 467 878
:
E-mail:dijaliza@bolnicasombor.org.rs
64
:
:
:
:
: 65
:22000
: 063 551 094
: 022 611 779
E-mail: anamikism@gmail.com
:
:
: ,
:
: 3
:24000
: 024 555 222
: 024 555 267
E-mail: belavuk@gmail.com; dijaliza@bolnicasombor.org.rs
:
:
:
:
: 78
:35230
: 035 470 773
: 035 474 306
E-mail: bolnicacuprija@nadlanu.com
:
:
:
:
: 17 :31000
: 031 562 254, 031 561 255/333
:
E-mail: jadrankamilinkovic@gmail.com
:
:
:
: .
: 70/6
:32000
: 032 355 014
: 032 307 043
E-mail: dijalza.cacak@gmail.com
65
:
:
:
: .
: 24
:15000
: 015 363 557
: 015 343 622
-mail: drn.zora@gmail.com
66